In a pioneer study, Oike et al. screened siRNA against SMARCA2 in a panel of SMARCA4 mutant NSCLC cell lines and found that the inhibition of SMARCA2 significantly decreased cell viability compared with control siRNA, whereas SMARCA4 wild-type cells were unaffected. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.